AU2004273965B2 - DNA vaccine compositions and methods of use - Google Patents

DNA vaccine compositions and methods of use Download PDF

Info

Publication number
AU2004273965B2
AU2004273965B2 AU2004273965A AU2004273965A AU2004273965B2 AU 2004273965 B2 AU2004273965 B2 AU 2004273965B2 AU 2004273965 A AU2004273965 A AU 2004273965A AU 2004273965 A AU2004273965 A AU 2004273965A AU 2004273965 B2 AU2004273965 B2 AU 2004273965B2
Authority
AU
Australia
Prior art keywords
dna
hiv
gene
immunogenic composition
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004273965A
Other languages
English (en)
Other versions
AU2004273965A1 (en
Inventor
Zhenqian Liu
Opendra Narayan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas Medical Center
Original Assignee
University of Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas Medical Center filed Critical University of Kansas Medical Center
Publication of AU2004273965A1 publication Critical patent/AU2004273965A1/en
Application granted granted Critical
Publication of AU2004273965B2 publication Critical patent/AU2004273965B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004273965A 2003-09-16 2004-09-16 DNA vaccine compositions and methods of use Ceased AU2004273965B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50319703P 2003-09-16 2003-09-16
US60/503,197 2003-09-16
US10/941,164 2004-09-15
US10/941,164 US7488485B2 (en) 2003-09-16 2004-09-15 DNA vaccine compositions and methods of use
PCT/US2004/030512 WO2005027844A2 (en) 2003-09-16 2004-09-16 Dna vaccine compositions and methods of use

Publications (2)

Publication Number Publication Date
AU2004273965A1 AU2004273965A1 (en) 2005-03-31
AU2004273965B2 true AU2004273965B2 (en) 2010-12-09

Family

ID=34381064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004273965A Ceased AU2004273965B2 (en) 2003-09-16 2004-09-16 DNA vaccine compositions and methods of use

Country Status (13)

Country Link
US (3) US7488485B2 (cg-RX-API-DMAC7.html)
EP (1) EP1667523B1 (cg-RX-API-DMAC7.html)
JP (1) JP4989224B2 (cg-RX-API-DMAC7.html)
AU (1) AU2004273965B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414442A (cg-RX-API-DMAC7.html)
CA (1) CA2538840C (cg-RX-API-DMAC7.html)
DK (1) DK1667523T3 (cg-RX-API-DMAC7.html)
ES (1) ES2399875T3 (cg-RX-API-DMAC7.html)
IL (1) IL174325A (cg-RX-API-DMAC7.html)
NZ (1) NZ545954A (cg-RX-API-DMAC7.html)
PL (1) PL1667523T3 (cg-RX-API-DMAC7.html)
PT (1) PT1667523E (cg-RX-API-DMAC7.html)
WO (1) WO2005027844A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use
US8765140B2 (en) * 2003-09-16 2014-07-01 University Of Kansas Medical Center DNA vaccine compositions with HIV/SIV gene modifications
ES2541771T3 (es) * 2005-05-03 2015-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Expresión de una proteína mitocondrial mediante un enfoque alotópico mejorado
US7585675B2 (en) * 2005-11-15 2009-09-08 University Of Kansas Medical Center Inhibition of HIV and SHIV replication with antisense interleukin-4
FR2979919B1 (fr) * 2011-09-12 2015-12-11 Centre Nat Rech Scient Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1
US20130337009A1 (en) * 2012-02-21 2013-12-19 Immunogenetix Therapeutics, Inc. Chimeric dna vaccine compositions and methods of use
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158131A1 (en) * 2000-10-23 2003-08-21 Anna Aldovini DNA vectors containing mutated HIV proviruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6531123B1 (en) * 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158131A1 (en) * 2000-10-23 2003-08-21 Anna Aldovini DNA vectors containing mutated HIV proviruses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Smith J.M. et al., Viral Immunology, 2000, Vol. no.13, no. 3, pages 343-351 *

Also Published As

Publication number Publication date
WO2005027844A3 (en) 2005-10-06
JP4989224B2 (ja) 2012-08-01
DK1667523T3 (da) 2013-01-21
US7488485B2 (en) 2009-02-10
PT1667523E (pt) 2013-02-04
US20120207782A1 (en) 2012-08-16
IL174325A (en) 2015-07-30
US8003113B2 (en) 2011-08-23
US20050112102A1 (en) 2005-05-26
US20090233857A1 (en) 2009-09-17
AU2004273965A1 (en) 2005-03-31
CA2538840C (en) 2014-02-18
CA2538840A1 (en) 2005-03-31
US8916174B2 (en) 2014-12-23
PL1667523T3 (pl) 2013-05-31
NZ545954A (en) 2009-04-30
ES2399875T3 (es) 2013-04-04
EP1667523B1 (en) 2012-11-21
WO2005027844A2 (en) 2005-03-31
EP1667523A2 (en) 2006-06-14
IL174325A0 (en) 2008-04-13
EP1667523A4 (en) 2007-12-19
JP2007505923A (ja) 2007-03-15
BRPI0414442A (pt) 2006-11-14

Similar Documents

Publication Publication Date Title
US8916174B2 (en) HIV DNA vaccine regulated by a caev-derived promoter
Voss et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine
JP2011530309A (ja) 多価ワクチン
CN101969996A (zh) 多价疫苗
US8785411B2 (en) HIV DNA vaccine methods of use
US7847085B2 (en) Recombinant HIV-1 gp120 immunogen with three different V3 loops from viruses of different clades
WO1994017825A1 (en) Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
Warren Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates
US5876724A (en) Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
Lecollinet et al. Vaccination against the feline immunodeficiency virus: the road not taken
EP0472706B1 (en) Induction of protection against viral infection
Singh et al. HIV vaccine development
ZA200603044B (en) DNA vaccine compositions and methods of use
MXPA06002993A (en) Dna vaccine compositions and methods of use
US20070010471A1 (en) HIV DNA vaccine
US20170107260A1 (en) Mosaic hiv-1 sequences and uses thereof
WO1993014126A1 (en) A major histocompatibility complex class ii antigen in a vaccine against an immunodeficiency virus
US20120321655A1 (en) Lentivirus vaccine based on the recombinant viral vaccine against yellow fever
McGettigan et al. HIV-1 vaccines: the search continues
Norley et al. Vaccine development using the simian immunodeficiency virus model for AIDS
Weaver Phylogenetic analysis of feline immunodeficiency virus and the development of a prophylactic genetic vaccine
Hostel Efficacy and their Delivery System: A Review

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired